Jump to page content Accessibility
News, views and contacts from the global Drugdevelopment industry
Login to drugdevelopment-technology.com Log in or Register
  • Home
  • Products & Services
  • Company A - Z
  • Projects
  • Features
  • Videos
  • White Papers
  • News
  • Events
  • Advertise With Us
Industry Projects | Projects by Region | Projects by Category | Archived Projects | Project Gallery
 

BG-12 (Dimethyl Fumarate), Treatment for Relapsing-Remitting Multiple Sclerosis (RRMS), United States of America



The damaged MS lesion.


  • Multiple sclerosis (MS) is caused when myelin insulation gets damaged.

  • Macrophages in the area of the lesion in an MS patient.

  • The damaged MS lesion.

Back to Project Details



Related Projects

Xolair - Biological Therapy
The product of a joint development programme between Tanox, Genentech...

Acomplia (Rimonabant) - Investigational Agent for the Management of Obesity
Developed by Sanofi-Aventis, Acomplia (rimonabant) is a selective...

Tarceva - Small Molecule
Tarceva (erlotinib) is an oral anti-cancer drug developed by...

Naproxcinod (HCT 3012) - COX-Inhibiting Nitric Oxide-Donator
Developed by French pharmaceutical company NicOx, naproxcinod (HCT 3012)...

Lyrica (Pregabalin) - New Gabapentinoid with Wide
Developed by Pfizer, pregabalin, marketed under the brand name Lyrica, is...

See all projects

Related News

Teva, Active Biotech enrol first patient in RRMS drug Phase III study
Teva Pharmaceutical Industries and Active Biotech have enrolled the...

Biogen, Sobi Phase III studies support recombinant Fc fusion proteins protection capability
Biogen Idec and Swedish Orphan Biovitrum (Sobi) have announced new data...

Biogen, Biovitrum begin paediatric trials of haemophilia A and B candidates
Biogen and Swedish Orphan Biovitrum have started two paediatric trials of...

Biogen Idec multiple sclerosis drug reports positive Phase 3 data
Biogen Idec's oral BG-12 (dimethyl fumarate) drug demonstrated safety...

Biogen Idec, Elan begins multiple sclerosis drug study
Biogen Idec and Elan Corporation are conducting a global Phase 3b...

Biogen Multiple Sclerosis Drug Meets Study Goals
Biogen has reported positive top-line results from the first of two Phase...

Russia First to Approve RRMS Drug Cladribine
The Russian Federal Service on Surveillance in Healthcare and...

Biogen and Swedish Orphan Biovitrum Advance Haemophilia Drug Trial
Biogen Idec and Swedish Orphan Biovitrum have decided to advance...

Roche and Biogen Halt Ocrelizumab Trials
Swiss firm Roche and US firm Biogen Idec have suspended the ongoing...

Biogen Kicks off Haemophilia B Trials
Biogen Idec and Swedish firm Orphan Biovitrum have begun dosing the...

See all news

Follow Us:
Twitter Twitter    Facebook Facebook   
Contact us
Advertise with us
Terms and conditions
Privacy
Links
Newsletter sign up
Online magazine sign up

drugdevelopment-technology.com is a product of Net Resources International. Copyright 2012 Net Resources International, a trading division of SPG Media Limited.